Altogether, these results show that gilteritinib can more effectively decrease tumor burden and target treatment-resistant KF cells, thereby improving response to VXL chemotherapy or venetoclax in FLT3-expressing ETP-ALL. Here, FLT3 is linked to neoplasm.